Reuters M&A roundup adds Marvell, Aspen Pharmacare; updates SpaceX
A roundup of reported bidding, M&A and asset-disposal news added Marvell Technology and Aspen Pharmacare and updated SpaceX as of Monday 14:30 GMT.
Related stories
Canaccord Genuity Group Agrees to Sell UK Wealth Management Business
Canaccord Genuity Group announced the sale of its wealth management business in the UK and Crown Dependencies to Centerbridge Partners and Mubadala Investment Company.
M impact | MNA | Nov 15, 2026, 11:26 PM UTC
Canaccord Genuity Agrees to CEO-Led Acquisition at About $15.27 Per Share
Canaccord Genuity agreed to be acquired by CEO Dan Daviau for approximately $15.27 per common share, based on the November 13 GBP/CAD rate. Closing is conditional on the UK wealth
M impact | MNA | Nov 15, 2026, 11:22 PM UTC
Canaccord Agrees to Sell UK Wealth Business for About £1.17B
Canaccord agreed to sell its UK and Crown Dependencies wealth business at an approximately £1.17B enterprise value. It expects about £564M in proceeds, with closing expected in the
M impact | MNA | Nov 15, 2026, 11:21 PM UTC
Canaccord Genuity Agrees to Sell UK Wealth Unit for £1.17B
The sale of CGWM UK carries approximately £1.17B in enterprise value, with about £564M in expected proceeds after adjustments. Closing is expected in H1 2027, subject to approvals.
M impact | MNA | Nov 15, 2026, 11:20 PM UTC
Canaccord Genuity Announces Sale of UK Wealth Management Business
Canaccord Genuity said it will sell its wealth management business in the UK and Crown Dependencies to Centerbridge Partners and Mubadala Investment Company.
M impact | MNA | Nov 15, 2026, 11:20 PM UTC
Australia’s IDP Rejects Blackstone’s Third Buyout Attempt at $564.5 Million Valuation
M impact | MNA | Nov 15, 2026, 11:10 PM UTC